Israel’s BioLight (see here previously) is partnering with Tel Aviv’s Sourasky (Ichilov) Medical Center, to locate and develop innovative technologies in ophthalmology. Also, Biolight’s subsidiary Diagnostear has begun a clinical trial in India of its diagnosis of Dry Eye Disease. … Continue reading →

Israel’s BioLight Life Sciences has completed a successful U.S. clinical study designed to assess the effectiveness of its TeaRx multi-assay test in evaluating tears’ components of patients suffering from dry eye syndrome (DES) as well as those of healthy subjects. … Continue reading →

Israel’s Micromedic Technologies, has identified several new genetic markers for predicting BRONJ (necrosis of the jawbone). BRONJ is a side effect of intravenous treatments in cancer and osteoporosis patients. http://www.bio-light.co.il/wp-content/uploads/2015/08/BRONJ-PR-clean-updated.pdf http://biotuesdays.com/2015/08/31/biolight-unit-identifies-bronj-genetic-markers/

Israel’s BioLight has announced the first sale of XLVision Sciences’ IOPtiMate to a medical center in Peru. The innovative CO2 laser system has previously been purchased by hospitals in Hong Kong, Poland, Hungary and Romania. (See Sep 2014 newsletter) http://www.bio-light.co.il/wp-content/uploads/2015/08/PR-Peru-final.pdf

Israel’s BioLight Life Sciences Investments announced that its CellDetect non-invasive test for detecting bladder cancer in urine has obtained CE Marking, enabling the product to be marketed and sold in Europe and other countries. http://www.bio-light.co.il/blog/eu-ce-mark-for-celldetect-non-invasive-test-for-detecting-recurrence-of-bladder-cancer/